Regulus Hits GSK Milestone
Luke Timmerman5/14/09
Regulus Therapeutics, the Carlsbad, CA-based developer of drugs that block microRNA targets, said today it has reached the first milestone as part of its partnership with GlaxoSmithKline. Regulus has delivered specific microRNA blockers, known as anti-MIRs, in mice, and shown how they change the expression of genes in immune cells. Regulus didn’t disclose any financial terms related to reaching the milestone. Regulus was founded as a joint venture of Carlsbad, CA-based Isis Pharmaceuticals (NASDAQ: ISIS) and Cambridge, MA-based Alnylam Pharmaceuticals (NASDAQ: ALNY).
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
Regulus Hits GSK Milestone | Xconomy « Biotech Beach Bum
5/19/09 10:53 am
[...] Regulus Hits GSK Milestone | Xconomy Regulus’s new microRNA blocker technology (aka anti-MIR) hits its first milestone for marketing/funding partner GSK. This promising approach delivers small pieces of RNA into cells to block transcription and thereby slow gene expression. http://www.xconomy.com/san-diego/2009/05/14/regulus-hits-gsk-milestone/ [...]